Synerlab buys Lyofal and IDD-Tech Orleans
CMO Synerlab has added lyophilisation and solid dosage form development capabilities to its offering with the acquisition of LyoFal and IDD-Tech Orleans.
The deals – terms of which were not disclosed – gives the contract manufacturing organisation (CMO) LyoFal’s 3,500sqm facility in Salon de Provence, France and its contract active pharmaceutical ingredient (API) and reagent freeze-drying business.
The IDD-Tech Orleans acquisition in contrast adds solid dosage form development, analytical services and pilot scale manufacturing capabilities.
Synerlab – which is majority owned by private-equity group AXA – operates three other production sites; a facility in Strasbourg that produces tablets and capsules; a plant in Vernouillet near Paris that makes both solid and liquid forms; and a sterile liquids factory that is also near the French capital.
